Search
Levoketoconazole
go.drugbank.com/drugs/DB05667Approved[A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … It possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersAminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnAminopterin is an amino derivative of folic acid, which was once used as an antineoplastic agent in the treatment of pediatric leukemia. … In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis.
Iophendylate
go.drugbank.com/drugs/DB01187ApprovedIophendylate is a mixture of isomers used as contrast medium, mainly for brain and spinal cord visualization. Iophendylate is a myelographic oil-ester (U.S. Patent 2,348,231). … In 1942 Van Wagenen (a neurosurgical colleague of Warrens, at the University of Rochester) identified Iophendylate as causing chemical meningitis in 30 patients where "space-displacing masses within the
Categories: Compounds used in a research, industrial, or household settingSynonyms: Ethyl 10-(p-iodophenyl)-undecanoate, Ethyl 10-(p-iodophenyl)undecylateOsilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigational[A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. … [A191910] As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsLevotofisopam
go.drugbank.com/drugs/DB19073InvestigationalLevotofisopam is under investigation in clinical trial NCT01519687 (Study of Levotofisopam 50 Mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout).
Talquetamab
go.drugbank.com/drugs/DB16678ApprovedInvestigationalTalquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. … [L47765] Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple myeloma cells, and CD3 on T cells.
Synonyms: ANTIBODY; BISPECIFIC GAMMA4 HEAVY CHAIN HUMANIZED AN, IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONALUmifenovir
go.drugbank.com/drugs/DB13609Investigational[A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational … Its invention is credited to a collaboration between Russian scientists from several research institutes 40-50 years ago, and reports of its chemical synthesis date back to 1993.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesLevomefolic acid
go.drugbank.com/drugs/DB11256ApprovedSupplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms. … Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773].
Mixtures: Medi-10, Hematron-AFSacubitril
go.drugbank.com/drugs/DB09292ApprovedInvestigationalSacubitril's active metabolite, LBQ657 inhibits neprilysin, a neutral endopeptidase that would typically cleave natiuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide ( … Under normal conditions, neprilysin breaks down other vasodilating peptides and also vasoconstrictors such as angiotensin I and II, endothelin-1 and peptide amyloid beta-protein.
Mixtures: ENTRESTO 100 MG, ENTRESTO 100 MGOxethazaine
go.drugbank.com/drugs/DB12532ApprovedWithdrawnIts actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal ulcer. … [A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations.
Mixtures: MUCAINE 200 ML SUSPANSIYONCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors